Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer

Mariangela Manicone, Cristina Poggiana, Antonella Facchinetti, Rita Zamarchi

Research output: Contribution to journalReview article

Abstract

Current therapeutic options for non-small cell lung cancer (NSCLC) patients are chemotherapy and targeted therapy directed mainly against epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Targeted therapy relies on the availability of tumor biopsies for molecular profiling at diagnosis and to longitudinally monitor treatment response and resistance development. Unfortunately, tumor biopsy might be invasive, recover poor material of suboptimal quality, and cause sample bias due to tumor heterogeneity. Many studies have illustrated the potential of liquid biopsy as minimal invasive approach to respond to the urgent need for real time monitoring, stratification, and personalized optimized treatment in NSCLC patients. In principle, the liquid biopsy could provide the genetic landscape of primary and metastatic cancerous lesions, detecting "druggable" genomic alterations or associated with treatment resistance. Moreover, it would guarantee the prognostic/predictive biomarkers evaluation in patients for whom biopsies are inaccessible or difficult to repeat. At this regard, the prognostic value of circulating tumor cells (CTCs) in NSCLC patients has been largely investigated, but still their clinical utility as tumor biomarker is hampered by the lack of a consensus on the criteria necessary and sufficient to define them and on the standard operating procedures (SOPs) for their assessment. This review will summarize current developments on liquid biopsy in NSCLC, addressing the technology issues that contribute to the poor ability to track CTCs in the blood of NSCLC patients, thus limiting their extensive use in the clinical practice, and analyzing the solutions adopted to overcome such limits, on the road towards the clinical validation.

Original languageEnglish
Pages (from-to)S1346-S1358
JournalJournal of Thoracic Disease
Volume9
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Biopsy
Circulating Neoplastic Cells
Therapeutics
Neoplasms
Tumor Biomarkers
Epidermal Growth Factor Receptor
Biomarkers
Technology
Drug Therapy
Mutation

Keywords

  • Circulating tumor cell (CTC)
  • CtDNA
  • Liquid biopsy
  • Non-small cell lung cancer (NSCLC)
  • Tumor marker

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer. / Manicone, Mariangela; Poggiana, Cristina; Facchinetti, Antonella; Zamarchi, Rita.

In: Journal of Thoracic Disease, Vol. 9, 01.10.2017, p. S1346-S1358.

Research output: Contribution to journalReview article

@article{8ac263bc4782440e9502ed07904c7ee6,
title = "Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer",
abstract = "Current therapeutic options for non-small cell lung cancer (NSCLC) patients are chemotherapy and targeted therapy directed mainly against epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Targeted therapy relies on the availability of tumor biopsies for molecular profiling at diagnosis and to longitudinally monitor treatment response and resistance development. Unfortunately, tumor biopsy might be invasive, recover poor material of suboptimal quality, and cause sample bias due to tumor heterogeneity. Many studies have illustrated the potential of liquid biopsy as minimal invasive approach to respond to the urgent need for real time monitoring, stratification, and personalized optimized treatment in NSCLC patients. In principle, the liquid biopsy could provide the genetic landscape of primary and metastatic cancerous lesions, detecting {"}druggable{"} genomic alterations or associated with treatment resistance. Moreover, it would guarantee the prognostic/predictive biomarkers evaluation in patients for whom biopsies are inaccessible or difficult to repeat. At this regard, the prognostic value of circulating tumor cells (CTCs) in NSCLC patients has been largely investigated, but still their clinical utility as tumor biomarker is hampered by the lack of a consensus on the criteria necessary and sufficient to define them and on the standard operating procedures (SOPs) for their assessment. This review will summarize current developments on liquid biopsy in NSCLC, addressing the technology issues that contribute to the poor ability to track CTCs in the blood of NSCLC patients, thus limiting their extensive use in the clinical practice, and analyzing the solutions adopted to overcome such limits, on the road towards the clinical validation.",
keywords = "Circulating tumor cell (CTC), CtDNA, Liquid biopsy, Non-small cell lung cancer (NSCLC), Tumor marker",
author = "Mariangela Manicone and Cristina Poggiana and Antonella Facchinetti and Rita Zamarchi",
year = "2017",
month = "10",
day = "1",
doi = "10.21037/jtd.2017.07.28",
language = "English",
volume = "9",
pages = "S1346--S1358",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer

AU - Manicone, Mariangela

AU - Poggiana, Cristina

AU - Facchinetti, Antonella

AU - Zamarchi, Rita

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Current therapeutic options for non-small cell lung cancer (NSCLC) patients are chemotherapy and targeted therapy directed mainly against epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Targeted therapy relies on the availability of tumor biopsies for molecular profiling at diagnosis and to longitudinally monitor treatment response and resistance development. Unfortunately, tumor biopsy might be invasive, recover poor material of suboptimal quality, and cause sample bias due to tumor heterogeneity. Many studies have illustrated the potential of liquid biopsy as minimal invasive approach to respond to the urgent need for real time monitoring, stratification, and personalized optimized treatment in NSCLC patients. In principle, the liquid biopsy could provide the genetic landscape of primary and metastatic cancerous lesions, detecting "druggable" genomic alterations or associated with treatment resistance. Moreover, it would guarantee the prognostic/predictive biomarkers evaluation in patients for whom biopsies are inaccessible or difficult to repeat. At this regard, the prognostic value of circulating tumor cells (CTCs) in NSCLC patients has been largely investigated, but still their clinical utility as tumor biomarker is hampered by the lack of a consensus on the criteria necessary and sufficient to define them and on the standard operating procedures (SOPs) for their assessment. This review will summarize current developments on liquid biopsy in NSCLC, addressing the technology issues that contribute to the poor ability to track CTCs in the blood of NSCLC patients, thus limiting their extensive use in the clinical practice, and analyzing the solutions adopted to overcome such limits, on the road towards the clinical validation.

AB - Current therapeutic options for non-small cell lung cancer (NSCLC) patients are chemotherapy and targeted therapy directed mainly against epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Targeted therapy relies on the availability of tumor biopsies for molecular profiling at diagnosis and to longitudinally monitor treatment response and resistance development. Unfortunately, tumor biopsy might be invasive, recover poor material of suboptimal quality, and cause sample bias due to tumor heterogeneity. Many studies have illustrated the potential of liquid biopsy as minimal invasive approach to respond to the urgent need for real time monitoring, stratification, and personalized optimized treatment in NSCLC patients. In principle, the liquid biopsy could provide the genetic landscape of primary and metastatic cancerous lesions, detecting "druggable" genomic alterations or associated with treatment resistance. Moreover, it would guarantee the prognostic/predictive biomarkers evaluation in patients for whom biopsies are inaccessible or difficult to repeat. At this regard, the prognostic value of circulating tumor cells (CTCs) in NSCLC patients has been largely investigated, but still their clinical utility as tumor biomarker is hampered by the lack of a consensus on the criteria necessary and sufficient to define them and on the standard operating procedures (SOPs) for their assessment. This review will summarize current developments on liquid biopsy in NSCLC, addressing the technology issues that contribute to the poor ability to track CTCs in the blood of NSCLC patients, thus limiting their extensive use in the clinical practice, and analyzing the solutions adopted to overcome such limits, on the road towards the clinical validation.

KW - Circulating tumor cell (CTC)

KW - CtDNA

KW - Liquid biopsy

KW - Non-small cell lung cancer (NSCLC)

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=85032261897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032261897&partnerID=8YFLogxK

U2 - 10.21037/jtd.2017.07.28

DO - 10.21037/jtd.2017.07.28

M3 - Review article

AN - SCOPUS:85032261897

VL - 9

SP - S1346-S1358

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

ER -